96 related articles for article (PubMed ID: 2258417)
21. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.
Dietz JD; Du S; Bolten CW; Payne MA; Xia C; Blinn JR; Funder JW; Hu X
Hypertension; 2008 Mar; 51(3):742-8. PubMed ID: 18250364
[TBL] [Abstract][Full Text] [Related]
22. In vitro plasma protein binding determination of flunarizine using equilibrium dialysis and liquid chromatography-tandem mass spectrometry.
Lin ZJ; Musiano D; Abbot A; Shum L
J Pharm Biomed Anal; 2005 Apr; 37(4):757-62. PubMed ID: 15797798
[TBL] [Abstract][Full Text] [Related]
23. Synthesis of new N3-substituted dihydropyrimidine derivatives as L-/T- type calcium channel blockers.
Teleb M; Zhang FX; Farghaly AM; Aboul Wafa OM; Fronczek FR; Zamponi GW; Fahmy H
Eur J Med Chem; 2017 Jul; 134():52-61. PubMed ID: 28399450
[TBL] [Abstract][Full Text] [Related]
24. Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia.
Lim SH; Anantharaman V; Teo WS; Chan YH
Resuscitation; 2009 May; 80(5):523-8. PubMed ID: 19261367
[TBL] [Abstract][Full Text] [Related]
25. Protection by Ca2+ channel blockers (nifedipine, diltiazem and verapamil) against the toxicity of oxidized low density lipoprotein to cultured lymphoid cells.
Nègre-Salvayre A; Salvayre R
Br J Pharmacol; 1992 Nov; 107(3):738-44. PubMed ID: 1472971
[TBL] [Abstract][Full Text] [Related]
26. In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).
Onoda JM; Nelson KK; Taylor JD; Honn KV
Cancer Res; 1989 Jun; 49(11):2844-50. PubMed ID: 2720644
[TBL] [Abstract][Full Text] [Related]
27. Effect of different Ca2+ entry blockers on dopamine-induced inhibition of in vitro prolactin secretion.
Di Renzo G; Amoroso S; Maida P; Canzoniero L; Nappi C; Taglialatela M; Annunzia L
Eur J Pharmacol; 1988 Feb; 146(2-3):201-6. PubMed ID: 3371396
[TBL] [Abstract][Full Text] [Related]
28. Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on thyrotropin- and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man.
Veldhuis JD; Borges JL; Drake CR; Rogol AD; Kaiser DL; Thorner MO
J Clin Endocrinol Metab; 1985 Jan; 60(1):144-9. PubMed ID: 3880562
[TBL] [Abstract][Full Text] [Related]
29. Calcium antagonists. Pharmacokinetic properties.
Kates RE
Drugs; 1983 Feb; 25(2):113-24. PubMed ID: 6339196
[TBL] [Abstract][Full Text] [Related]
30. [Electrophysiologic effects of calcium channel blockers on supraventricular tachycardia in children].
Fujino H; Fujiseki Y; Shimada M
J Cardiol; 1989 Mar; 19(1):307-15. PubMed ID: 2810047
[TBL] [Abstract][Full Text] [Related]
31. [Calcium channel blockers in heart failure].
Hole T; Dickstein K; Gundersen T; Kjekshus J; Myhre ES; Rønnevik PK; Westheim AS
Tidsskr Nor Laegeforen; 1997 Jun; 117(16):2329-32. PubMed ID: 9265278
[TBL] [Abstract][Full Text] [Related]
32. Clinical use of calcium antagonists in hypertension: update 1986.
Lund-Johansen P
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S29-35. PubMed ID: 2455135
[TBL] [Abstract][Full Text] [Related]
33. Analgesic effects of several calcium channel blockers in mice.
Del Pozo E; Caro G; Baeyens JM
Eur J Pharmacol; 1987 Jun; 137(2-3):155-60. PubMed ID: 3609138
[TBL] [Abstract][Full Text] [Related]
34. Bis(benzylisoquinoline) analogs of tetrandrine block L-type calcium channels: evidence for interaction at the diltiazem-binding site.
Felix JP; King VF; Shevell JL; Garcia ML; Kaczorowski GJ; Bick IR; Slaughter RS
Biochemistry; 1992 Dec; 31(47):11793-800. PubMed ID: 1332772
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the effects of the calcium entry blockers, verapamil, diltiazem and flunarizine against contractions of the rat isolated aorta and portal vein.
Marriott JF
Br J Pharmacol; 1988 Sep; 95(1):145-54. PubMed ID: 3219471
[TBL] [Abstract][Full Text] [Related]
36. Effects of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition.
Bauer JH; Sunderrajan S; Reams G
Am J Cardiol; 1985 Dec; 56(16):62H-67H. PubMed ID: 2933950
[TBL] [Abstract][Full Text] [Related]
37. Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.
Opie LH
Q J Med; 1984; 53(209):1-16. PubMed ID: 6324268
[TBL] [Abstract][Full Text] [Related]
38. Some similarities and differences between verapamil and the dihydropyridines.
Antonios TF; MacGregor GA
J Hypertens Suppl; 1998 Jan; 16(1):S31-4. PubMed ID: 9534094
[TBL] [Abstract][Full Text] [Related]
39. Cellular actions and pharmacology of the calcium channel blocking drugs.
Katz AM; Hager WD; Messineo FC; Pappano AJ
Am J Med; 1984 Aug; 77(2B):2-10. PubMed ID: 6486125
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous determination of a new dihydropyridine calcium antagonist (MPC-1304) and its metabolite in dog plasma by high-performance liquid chromatography with electrochemical detection.
Iida Y; Kinouchi Y; Takeichi Y; Imai T; Otagiri M
J Chromatogr; 1991 Nov; 571(1-2):277-82. PubMed ID: 1810957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
